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Alipogene tiparvovec (Glybera®) is an adeno-associated virus serotype 1 (AAV1)-based
gene therapy that has been developed for the treatment of patients with lipoprotein lipase
(LPL) deficiency. Alipogene tiparvovec contains the human LPL naturally occurring gene
variant LPLS447X in a non-replicating viral vector based on AAV1. Such virus-derived vec-
tors administered to humans elicit immune responses against the viral capsid protein and
immune responses, especially cellular, mounted against the protein expressed from the
administered gene have been linked to attenuated transgene expression and loss of effi-
cacy. Therefore, a potential concern about the use of AAV-based vectors for gene therapy
is that they may induce humoral and cellular immune responses in the recipient that may
impact on efficacy and safety. In this paper, we review the current understanding of immune
responses against AAV-based vectors and their impact on clinical efficacy and safety. In par-
ticular, the immunogenicity findings from the clinical development of alipogene tiparvovec
up to licensing in Europe will be discussed demonstrating that systemic and local immune
responses induced by intra-muscular injection of alipogene tiparvovec have no deleterious
effects on clinical efficacy and safety.These findings show that muscle-directed AAV-based
gene therapy remains a promising approach for the treatment of human diseases.
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INTRODUCTION
Adeno-associated virus (AAV) is a naturally occurring virus that
is known to infect humans and other primates. It is expected to
interact at multiple levels with the innate and adaptive immune
system and elicit immune responses when injected in man. AAV-
based vectors are nowadays often chosen for the development of
new, promising gene therapy approaches because of several inter-
esting features such as their inability to self-replicate. However, a
potential concern about the use of such virus-derived vectors is
the potential to induce humoral and cellular immune responses in
the recipient that may impact on efficacy and safety. In this report,
we review the current understanding of immune responses against
AAV-based vectors and their impact on clinical efficacy and safety
using alipogene tiparvovec (Glybera®) as an example. Glybera®
has received marketing authorization under exceptional circum-
stances in Europe in 2012. Alipogene tiparvovec is an AAV-based
gene therapy vector that has been developed for the treatment of
patients with lipoprotein lipase deficiency (LPLD). It contains the
gene of the naturally occurring gain-of-function variant LPLS447X
of the human lipoprotein lipase (LPL) in a non-replicating viral
vector based on adeno-associated virus serotype 1 (AAV1). The
immunogenicity findings from the clinical development of alipo-
gene tiparvovec will be discussed, demonstrating that systemic and
local immune responses induced by intra-muscular injection of
alipogene tiparvovec have not shown deleterious effects on clin-
ical efficacy and safety. Alipogene tiparvovec is an example that
muscle-directed AAV-based gene therapy is a promising approach
for the treatment of human diseases.
PARTICULAR FEATURES OF AAV AND AAV-VECTORS
Wild-type AAV is not associated with any known disease or pathol-
ogy in humans (1, 2). In addition, the virus is naturally replication-
defective and requires a helper virus such as adenovirus to replicate
(3). Wild-type AAV also has been shown in vitro to have the abil-
ity to stably integrate into the host cell genome at a specific site
(designated AAVS1) in the human chromosome 19 with mini-
mal risk for random incorporations into the genome. For these
reasons, AAV has attracted considerable interest because of its
potential as a gene therapy vector. The use of AAV as gene ther-
apy vectors has required the elimination of the rep gene from the
vector, since it is coding for the protein that is involved in replica-
tion of the viral DNA and site-specific integration. In the vector
genome, the rep and cap genes are replaced by the transgene, in
the case of alipogene tiparvovec the gene for LPL, together with
a promoter that is necessary to drive transcription. This cassette
is flanked by inverted terminal repeats (ITRs) that are necessary
for the formation of so-called concatemers in the nucleus after
the single-stranded vector DNA is converted by host cell DNA
polymerase complexes into double-stranded DNA. These episo-
mal concatemers remain intact in the nucleus of non-dividing
host cells. Hence, transferred genomes tend to persist inside the
cells mainly in this episomal, non-integrated form (4, 5). The gen-
eration of AAV-vectors currently used for gene therapy in humans
has strongly reduced the risk of insertional mutagenesis (6–8). As
a result, AAV-vectors are among the simplest gene therapy vec-
tors, containing only the transgene expression cassette flanked by
two non-coding viral ITRs, and enclosed in a capsid composed of
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three structural proteins, VP1, 2, and 3 (9). Alipogene tiparvovec
indeed is such an AAV-vector and contains the transgene coding
for LPLS447X.
Another important feature of AAV and also of AAV-based vec-
tors is their very low immunogenic potential. Immune responses
against AAV in general seem restricted and mainly consist in the
generation of neutralizing antibodies, while well-defined cytotoxic
responses seem minimal (10). This feature, along with the ability
to infect quiescent cells, is another important advantage for AAV
for their use as vectors for human gene therapy. Presumably several
features of AAV contribute to this low immunogenicity, including
the simplicity of AAV-vectors and their low efficiency in transduc-
ing professional antigen presenting cells such as macrophages or
dendritic cells, and their lacking capacity to express viral proteins
(11, 12).
NON-CLINICAL INVESTIGATIONS ON THE IMMUNOGENICITY OF
AAV-VECTORS
A large number of studies in various animal species have demon-
strated the potential of AAV-vectors as a therapeutic platform for
gene delivery (13–22). However, the AAV capsid protein as well
as the transgene product can interact at multiple levels with the
innate and adaptive immune system. Consistent with current con-
cepts in immunology, the immune response can vary substantially
depending upon the tissue which is targeted, with outcomes rang-
ing from almost unresponsiveness (gene transfer in the eye or in
the brain) to responsiveness (gene transfer in the muscle, liver, or
lung). Humoral immune responses to AAV capsid proteins were
reported in all animal studies in which AAV-vectors were used
to target muscle or liver. While cellular and humoral immune
responses to AAV were reported to be modest in intensity in
mouse models (23–25), cytotoxic T-cell responses to AAV-vector
and transgene product in muscle of large animal models have been
recently reported, which emphasizes the importance of appropri-
ate animal models to address safety and efficacy of the approach
and predict clinical outcomes (26).
CLINICAL STUDIES WITH AAV-GENE THERAPY VECTORS IN HUMANS
Over the last two decades, numerous clinical studies were per-
formed using AAV to deliver therapeutic genes to different organs
and tissues including muscle, liver, and the CNS. Those studies
included hundreds of patients and indicate an excellent safety
record of AAV-vectors for gene therapy in humans. The differ-
ent safety aspects of AAV for the use in humans have recently been
summarized elsewhere [see for review Ref. (23, 26, 27)].
Immune responses have been assessed in clinical trials by mea-
suring systemic and local cytotoxic reactions as well as (neutral-
izing) antibodies against AAV and/or the expressed therapeutic
protein (24, 25, 28–37). Results from these measurements in these
clinical studies indicate that the immune responses measured
could impact on the efficacy of the product rather than the overall
safety profile. The immunogenicity data reported so far show that
immune responses against AAV capsid proteins can vary widely
and amongst others are influenced by the target organ, route of
delivery, and dosing schedule.
The eye and central nervous system are known to be immune-
privileged compartments of the body due to adaptations that
limit immune responses. Delivery of AAV-vectors directly into
the brain has been tested in a number of studies (31, 38–40).
Similarly, subretinal vector delivery has been performed in a num-
ber of clinical studies (28, 33). In all these studies, AAV-vector
administration was associated with little or no detectable immune
response to the capsid or the transgene protein in serum and
peripheral blood mononuclear cell (PBMC). In contrast, humoral
immune responses to AAV capsid proteins were reported in all
trials targeting AAV-based vectors to muscle or liver.
Cellular immune responses against the AAV-vector have been
found in only some of the clinical trials performed. The first
observation of a cellular immune response induced by AAV-gene
therapy to our knowledge was in patients with hemophilia B who
were treated with an AAV-vector to deliver human coagulation
factor IX (24, 27, 41, 42). In this study, a cell-mediated immune
response to AAV2 capsid was reported, which was measured in
parallel with a loss of transgene expression. In a more recent clin-
ical study in patients with hemophilia B, using the capsid of AAV8
to deliver FIX to the liver, similar reactions were observed in some
of the patients treated with the highest dose (37). Whereas both
studies in patients with hemophilia B indicate a direct correla-
tion between the induction of a CD8 T-cell response toward the
AAV capsid proteins and a loss of transgene expression, this seems
not to be the case after intra-muscular administration of an AAV-
vector. In a clinical study in patients with α-1 antitrypsin (AAT)
deficiency in which the gene for AAT was delivered by an AAV1
capsid, cellular immune responses were found against the capsid
proteins from day 14 in all subjects. However, the influence of
those T-cells is not clear since the expression of the transgene was
sustained at sub-therapeutic levels in all subjects. These data sug-
gest that the cellular immune responses to the AAV capsid did not
eliminate the transduced cells (25). Similarly, systemic and local
cellular immune responses induced by intra-muscular injection of
alipogene tiparvovec did not appear to have an impact on safety
and did not prevent clinical efficacy (43). However, cellular host
immune responses to both AAV capsid and transgene products
have been shown in the context of muscular dystrophy (26).
CLINICAL STUDIES WITH ALIPOGENE TIPARVOVEC
Alipogene tiparvovec (called AAV1–LPLS447X in the early phases
of clinical development) is an AAV1 vector expressing a natu-
rally occurring variant of the LPL transgene, LPLS447X, associated
with improved lipid profile and carried by approximately 20%
of the general population (44). Building on successful proof-of-
concept studies in animal models (45, 46), three interventional
clinical studies have been conducted with alipogene tiparvovec
in patients with LPL-deficiency (CT-AMT-010, CT-AMT-011-01,
CT-AMT-011-02) (Figure 1). In all studies, alipogene tiparvovec
was administered via multiple direct intra-muscular injections
into the lower extremities in the subjects with LPL-deficiency.
Alipogene tiparvovec was administered with a 22 gage needle as
multiple injections of 0.5 ml volume (maximum) with a distance
of 2.5–3 cm between each site. The total number of injections was
divided equally between the vastus lateralis and vastus medialis of
both the left and right musculus femoralis. The calf muscles were
also injected if the number of injections exceeded 40 injection sites.
Both the muscle and major blood vessels were identified prior to
Frontiers in Immunology | Microbial Immunology March 2014 | Volume 5 | Article 82 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ferreira et al. Immunosafety of AAV1 gene therapy in muscle
FIGURE 1 | Summary of the clinical studies with alipogene tiparvovec.
injection using ultrasound to ensure intra-muscular administra-
tion, and to avoid intra-vascular injection. Two injection sites were
labeled with permanent skin tattoos so that injection sites could
be identified for subsequent biopsy. The total dose delivered to
subjects was calculated based upon the subject’s body weight and
his/her allocation to a specific dosing cohort.
CLINICAL DEVELOPMENT PROGRAM
Study CT-AMT-010
Eight patients with LPL-deficiency were first monitored for sev-
eral months, and then treated once with multiple intra-muscular
injections of AAV1–LPLS447X (predecessor of alipogene tiparvovec
containing the same construct but manufactured in another cell
system). The patients did not receive immunosuppressants pre- or
post-exposure to AAV1–LPLS447X, and were followed-up for up to
18 months after administration in the active phase of the study.
Study CT-AMT-011-01
After an observation period of a few months, 14 patients with LPL-
deficiency were treated with alipogene tiparvovec. Twelve of these
patients received immunosuppressants. The immunosuppressant
regimen consisted of cyclosporine A at a dose of 3 mg/kg/day and
mycophenolate mofetil at a dose of 2 g/day and was maintained
until 12 weeks after administration of alipogene tiparvovec. The
patients were followed-up for 5 years after administration.
Study CT-AMT-011-02
After a run-in phase of a few months, five patients with LPL-
deficiency were treated with alipogene tiparvovec. All patients have
received immunosuppressants, starting shortly before exposure to
alipogene tiparvovec. The immunosuppressant regimen consisted
of 3 mg/kg/day cyclosporine A, 2 g/day mycophenolate mofetil,
and a bolus injection of methylprednisolone was given 30 min
prior to alipogene tiparvovec administration. The immunosup-
pressant regimen with cyclosporine A and mycophenolate mofetil
was maintained until 12 weeks after exposure. The patients were
followed-up for a year after administration in the active phase of
the study.
A summary of the clinical analyses schedule with alipogene
tiparvovec is given in Figure 2. The follow-up scheme included
routine hematology and biochemistry up to 3 months, immunol-
ogy monitoring up to 1.5 years, and a biopsy of the injected muscle.
No hematology visits were planned after week 12. Antibodies as
well as cellular responses against AAV1 and LPL were monitored
in the long-term follow-up at 2, 3, 4, and 5 years after administra-
tion of alipogene tiparvovec. Blood samples were obtained from
all subjects enrolled in the clinical trials pre- and up to 5-year
post-administration of alipogene tiparvovec, and analyzed for the
presence of total antibodies against AAV1 capsid proteins and LPL
by ELISA-based assay. In addition, all blood samples were tested
for presence of T-cells specific for AAV with an enzyme-linked
immunospot (ELISpot) assay. Of note, patients with pre-existing
total antibodies against AAV1 were included in the clinical trials.
Biopsy specimens of the injected muscle as well as specimens
from the non-injected muscle (control) were taken between 10
and 52 weeks after injection for immunohistochemical studies.
The specimens were analyzed for the presence and the nature
of any cellular infiltrates. In addition, blood samples were tested
at regular intervals for inflammation markers such as C-reactive
protein (CRP) and neutrophil counts, as well as for parameters
reflecting local (inflammatory) muscle damage such as creatine
phosphokinase (CPK).
IMMUNOLOGICAL MEASUREMENTS IN THE CLINICAL PROGRAM OF
ALIPOGENE TIPARVOVEC
Antibodies against AAV1 capsid proteins
Humoral (total antibodies) responses against AAV1 capsid pro-
teins were measured with an ELISA assay. Briefly, AAV1 capsid
proteins were fixed to polystyrene ELISA plates and incubated
with the serum samples to be tested. Bound antibodies were
detected by a subsequent incubation with conjugated antibodies
against human immunoglobulins. The ELISA did not discriminate
between IgG subclass antibodies. To discriminate between samples
with normal and with elevated levels of anti-AAV antibodies, a
cut-off level was established using serum samples from 30 healthy
volunteers. The test results of the samples to be tested were scored
by comparison with those of the negative control, which was a
serum sample from a healthy human control. To this end, algo-
rithms were developed to convey the optical density results into a
semi-quantitative scoring system. Based on the algorithms, sam-
ples were said to be strongly positive (++), weakly positive (+),
or negative (−) for AAV1 total antibodies.
Antibodies against LPL
Antibody responses against LPLS447X were assessed by measuring
total antibody levels in pre- and post-exposure serum samples
with an ELISA assay. This ELISA was similar to that described
above for antibodies against AAV1 proteins, except that recom-
binant LPL was used to coat plates. The recombinant LPLS447X
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FIGURE 2 | Clinical analyses schedule of the studies with alipogene tiparvovec until 1.5 years after drug delivery.
was isolated from medium of stably transfected CHO cells that
express LPLS447X. The ELISA did not discriminate between IgG
subclass. A cut-off level of the assay was established in a similar
way as described in the previous paragraph for anti-AAV1 anti-
body ELISA. Also for this ELISA, an algorithm was developed to
convey the optical density results into a semi-quantitative scoring
system. Based on the algorithms, samples were said to be positive
(+) or negative (−) for anti-LPL antibodies.
Assay for AAV1-specific T-lymphocytes
In order to monitor the T-cell-mediated immune response in the
patients treated with alipogene tiparvovec, an ELISpot assay was
developed. This assay is based on the detection and quantifica-
tion of interferon gamma (IFN-γ) secreting cells upon stimulation
with AAV1 capsid antigens. To this end, PBMCs were obtained
from the patients and incubated with AAV1 capsid antigens. A
one color ELISpot assay was used for this purpose as previously
described (23, 24) and further validated by a contract research lab-
oratory, SeraCare Life sciences (Milford, MA, USA), according to
predefined QA/QC specifications.
Two criteria are widely used to evaluate test results of ELISpot
assays, which are the number of spot forming unit (SFU) per mil-
lion cells upon stimulation with antigen and the increase of SFU
number compared to that in medium only. Generally, samples are
said to be positive for T-cells when upon stimulation with antigen
they contain >50 SFU per million cells, and when that number is
at least threefold higher than that of the medium control. These
criteria were also used to assess T-cells against AAV1.
Immunohistochemical analysis
Open muscle biopsies were collected between 10 and 52 weeks after
intra-muscular injection of AAV1–LPL from both an injected (tat-
tooed) muscle (vastus lateralis) and a non-injected control muscle
site (not tattooed musculus tibialis anterior). The specimens were
analyzed according to routine evaluations, including muscle his-
tology and immunohistochemical characterization of infiltrating
cells when present. The biopsy procedures were performed at
variable time after injection mainly dependent on the availabil-
ity of the patients. The predefined criteria for the collection of
tissue specimens in the protocol were 14 weeks for the first biopsy
and 52 weeks for the follow-up biopsy, independently of any clin-
ical indication. However, due to the availability of the patients,
deviations from the protocol occurred and the real time of col-
lection of the biopsy specimens is reported for each patient in
Figure 3. Specimens from the injected muscle were compared to
those from the contralateral non-injected muscles from each sub-
ject. The histological assessments were carried out according to
routine procedures at the Department of Neuropathology, Aca-
demic Medical Centre (AMC), Amsterdam, The Netherlands, by
Dr. Dirk Troost and Dr. Eleonora Aronica, both specialized in the
histopathology of human muscle. Tissues’ scoring was expressed
as negative to 3+ positive.
ANALYSIS OF THE TREATMENT-EMERGENT IMMUNE
RESPONSES IN THE PATIENTS TREATED WITH ALIPOGENE
TIPARVOVEC
An overview of the systemic as well as local humoral and cellu-
lar immune responses observed in all patients participating in the
clinical studies is shown in Figures 3A–C. It should be noted that
only 19 patients gave their consent to have muscle biopsies taken, 7
patients from study CT-AMT-010, 7 from study CT-AMT-011-01,
and 5 from study CT-AMT-011-02.
HUMORAL IMMUNE RESPONSES UPON TREATMENT WITH ALIPOGENE
TIPARVOVEC
Fifteen of the 26 subject had pre-existing antibodies against AAV1.
Among the 19 patients of whom a post-exposure biopsy was
available, 11 had pre-existing anti-AAV antibodies. No apparent
relationship was found between pre-existing AAV1 antibodies and
LPL-expression after administration of alipogene tiparvovec: 7 of
the 11 patients with pre-existing anti-AAV1 antibodies had LPL-
expression in the biopsy versus 4 of the 7 patients with no such
antibodies (Figure 3). As expected, and in line with published data
observed with other AAV-vectors all subjects, whether exhibiting
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pre-existing antibodies or not, showed a treatment-emergent anti-
AAV1 total antibody response, which became detectable at 1 or
2 weeks after the admginistration of alipogene tiparvovec. The
anti-AAV1 total antibody titers measured at those early time
points remained stable over the whole observation period. The
responses of circulating antibodies against AAV1 observed in the
clinical development program with alipogene tiparvovec are con-
sistent with data reported for other published gene therapy trials
with AAV-based vectors [among others, Ref. (25, 41, 42, 47)].
In each patient, an increase in the level of anti-AAV antibody
titers was observed upon administration of alipogene tiparvovec,
which was sustained overtime. There was no apparent difference
in anti-AAV1 antibody response between studies and dose cohorts
suggestive that the dose and/or the immunosuppressive regime
did not influence anti-AAV1 total antibody formation.
None of the patients had anti-LPL antibodies prior to the
administration of alipogene tiparvovec nor developed those after
delivery of the product. The baseline levels of anti-LPL antibod-
ies were below the cut-off level of detection in all patients prior to
administration of alipogene tiparvovec. Post-administration levels
FIGURE 3 | Continued
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FIGURE 3 | A per-patient summary of the immunological data obtained
in study CT-AMT-010 (A), CT-AMT-011-01 (B), and CT-AMT-011-02 (C).
Biopsies: the scoring of LPL-expression in injected muscle tissue reflect the
number of cells positive for lipid deposits, as identified using oil red O staining
of cross-sections: 0, −, 1+, rare; 2+, moderate; 3+, high number. The scoring
of T-cells infiltrates in injected muscle tissue reflect the number of infiltrates
observed, as identified using staining of cross-sections with cell-specific
markers: 0, −, 1+, rare; 2+, moderate; 3+, high number. It should be noted
that the scores given are arbitrary, simply providing a semi-quantitative or
relative means to distinguish between patients in terms of amount of
inflammatory cells observed. As such, a score of 3+ represents the highest
score observed in the study. Systemic T-cells responses: samples were said
to be positive for T-cells when upon stimulation with antigen they contained
>50 SFU per million cells, and when that number was at least threefold
higher than that of the medium control. A T-cell response to the antigen was
reported transient positive (transient) when at least two consecutive sampling
time points were measured positive in the ELISpot assay. The patient
reported “sporadic” present recurrent non-consecutive T-cell response over
time. When none or only one sampling time was measured positive, the T-cell
response was reported negative (−). Antibodies: the test results of the
samples were scored by comparison with those of a negative control (a
serum sample from a healthy human control). To this end, algorithms were
developed to convey the optical density results into a semi-quantitative
scoring system. Based on the algorithms, samples were said to be strongly
positive (++), weakly positive (+), or negative for AAV1 antibodies and
positive (+) or negative (−) for anti-LPL antibodies.
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remained below the cut-off level, demonstrating that no antibody
responses were mounted against the expressed LPL protein after
administration of alipogene tiparvovec even in the long-term.
CELLULAR IMMUNE RESPONSES UPON TREATMENT WITH ALIPOGENE
TIPARVOVEC
Enzyme-linked immunospot assays were used to assess the course
of numbers of T-cells in peripheral blood that were directed against
AAV1 epitopes. The results obtained across studies and per subjects
are given in Figures 4A–C. In study AMT-010 (48), the intra-
muscular administration without immune suppression of the
AAV1 vector in humans resulted in a transient T-cell activation in
four of eight subjects. In study AMT-011-01 (49), cellular immune
responses against AAV1 capsid proteins were also observed despite
immune suppression. On the basis of the data obtained from
PBMCs of adequate quality, a moderate and non-persistent T-
cell response was observed directed against the AAV1 capsid in
9 out of the 14 subjects. Therefore, the immunosuppressive reg-
imen was further optimized in study CT-AMT-011-02 (50) by
starting administration of cyclosporine and MMF administration
earlier before alipogene tiparvovec administration, and by adding
a bolus injection of methylprednisolone at the time of alipogene
tiparvovec administration. However, in study CT-AMT-011-02,
comparable cellular immune responses against AAV1 capsid pro-
teins were observed as in study CT-AMT-011-01. Overall, transient
cellular immune responses did not have clinical consequences
as they were not associated with any clinical signs or symptoms
such as persistent elevation of blood levels of CRP, CPK, or other
inflammation markers (see Adverse Events).
Enzyme-linked immunospot assays were also used to evaluate
whether there was any T-cell responses against the expressed LPL
protein product. In none of the patients, such immune responses
were observed upon administration of alipogene tiparvovec at
any dose.
LOCAL T-CELL RESPONSES
Biopsy specimens of the injected muscle from 19 patients were
available for immunohistochemical analyses. As described previ-
ously, these specimens were assessed for the presence of inflam-
matory cell infiltrate by qualified histopathologists. Infiltrates of
varying intensity consisting of B cells, macrophages, and mainly
T-cells, were found in 15 patients whereas in the other 4, no inflam-
matory cell infiltrate was observed. However, as illustrated in study
AMT-011-02 with subject 02-002 for which no infiltrates in the
injected muscle was detected, the biopsy of some subjects was
taken weeks after the peak of systemic T-cells response reached
baseline, compared to a few weeks for others subjects. Therefore,
the time of the biopsy should be taken into consideration when
putting in parallel local and systemic T-cell responses.
As none of the patients developed a T-cell response against
LPL, the relation between an immune response to the transgene
and the presence of a local T-cell infiltrate was not further inves-
tigated. The presence of cytotoxic T-lymphocytes (CTL) in the
inflammatory cell infiltrates was investigated in the muscle tissues
injected with alipogene tiparvovec as well as in muscle biopsies
from non-injected muscle. As a parameter for cellular cytotoxicity,
granzyme B and Fas ligand expression by the cells was measured.
CD8-positive T-cells in the infiltrates were negative for granzyme
B and Fas ligand expression, which suggest that the majority of the
T-lymphocytes present in the injected muscle tissue lack cytotoxic
properties. Furthermore, CD4-positive T-cells observed in muscle
biopsies from LPLD subjects injected with alipogene tiparvovec
FIGURE 4 | Continued
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FIGURE 4 | Systemic cellular immune responses following
alipogene tiparvovec administration. The tables below provides
an overview of the individual patient systemic T-cell response
against AAV1 overtime for study CT-AMT-010 (A), study AMT-011-01
(B), and study AMT-011-02 (C). We considered that a subject
developed a T-cell-mediated immune response to AAV1 capsid
proteins when at least two of the eight to nine sampling time
points were measured positive (+) in the ELISpot assay. When only
one sampling time was reported positive (+), the T-cell response
was considered negative.
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were further assessed for the expression of the transcription factor
FoxP3, as a marker for regulatory T-cells. FoxP3-positive/CD4-
positive T-cells were also found in the infiltrates suggesting that
multiple mechanisms contribute to the local immune tolerance to
alipogene tiparvovec administration (50).
IMMUNOGENICITY OF ALIPOGENE TIPARVOVEC AND
EFFICACY
The presence of LPL protein in the muscle biopsies and the
improved clearance of post-prandial chylomicrons levels in plasma
were used to measure local and systemic activity of alipogene tipar-
vovec and were considered as efficacy markers (49, 51). However,
the use of muscle biopsies has several hindrances. At first, out of
the 27 patients treated with alipogene tiparvovec, 19 patients gave
their consent for a muscle biopsy once. Only one patient allowed
the procedure to be done twice. Second, the results were influenced
by the limited spread of the product in the muscle tissue and the
variability in the procedure, as not all biopsies were consistently
taken in close proximity to the actual injection site. Therefore, the
circulating chylomicrons plasma levels measurement was devel-
oped in parallel to the clinical study CT-AMT-011-01 and used
as a primary end point only in the study CT-AMT-011-02, as the
most reliable endpoint to determine the systemic activity of the
LPL enzyme.
Fifteen of the 26 patients, with registered data for presence of
pre-administration anti-AAV1 antibodies, had pre-existing anti-
bodies against AAV1. Among the 15 patients with pre-existing
antibodies against AAV1, biopsies were obtained from 11 patients.
Among those 11 patients, 7 had LPL-expression in the biopsy.
In comparison, from the 11 patients without pre-existing anti-
bodies, 8 muscle biopsies were obtained; and from those, 5 were
stained positive for LPL-expression. This distribution was very
similar across the three studies CT-AMT-010, CT-AMT-011-01,
and CT-AMT-011-02. Our results strongly indicate that there was
no apparent relationship between the presence of pre-existing
AAV1 antibodies in LPLD patients and LPL-expression after
administration of alipogene tiparvovec.
After the administration of alipogene tiparvovec in all 27
patients, the development of treatment-emergent antibodies
against AAV1 capsid proteins was observed, independently of
whether pre-existing antibodies were present or not. In rela-
tion with efficacy, those treatment-emergent antibody responses
against the AAV1 capsid proteins upon treatment with alipogene
tiparvovec, did not seem to affect expression of the transgene.
A similar conclusion as drawn for the presence and develop-
ment of AAV1-specific antibodies can be drawn for the develop-
ment and presence of AAV-specific T-cells after administration of
alipogene tiparvovec. The percentage of patients with treatment-
emergent T-cell response across studies and among the three dose
groups was 50% (2/4) of the subjects treated with 1× 1011 gc/kg
having a positive response, 40% (4/10) of the patients treated
with 3× 1011 gc/kg, and 69% (9/13) of the patients treated with
1× 1012 gc/kg, which suggest an AAV1-dose-dependent kinetics
of T-cell response appearance (48–50). Of the 19 patients who
consented to the biopsy procedure, 10 developed AAV1-specific T-
cells. Of those 10 patients, 5 were tested positive for the expression
of LPL in the biopsies. Of the 9 patients with no detectable T-cell
response against AAV1, 7 had detectable LPL-expression in their
biopsy. In relation with efficacy, those transient T-cell responses
against the AAV1 capsid proteins upon treatment with alipogene
tiparvovec, did not seem to directly influence the expression of the
transgene.
However, as mentioned previously, the variability of the biopsy
procedure and by consequence, the difficulty for quantification
and comparison between patients has to be considered in the
interpretation of the data. The differences in the results obtained
with the biopsies of patient 01-001 (in study CT-AMT-011-02),
collected at 18 and 52 weeks after administration of alipogene
tiparvovec, illustrate this issue. The biopsy taken at week 18 yielded
no detectable LPL-expression, whereas the biopsy taken at week
52 yielded a strong expression of LPL.
The administration of alipogene tiparvovec resulted in func-
tional LPL activity levels sufficient to achieve a beneficial clinical
effect in patients with LPLD. This conclusion is supported by the
evidence that levels of plasma TG decreased in LPLD patients after
administration of alipogene tiparvovec. The data obtained in stud-
ies CT-AMT-010, without immunosuppression, and CT-AMT-
011-01 and AMT-011-02, with immunosuppression, are consid-
ered comparable in terms of the decrease in TG levels (Figure 5).
However,plasma TG levels subsequently increased in most patients
around 12–14 weeks post-administration of alipogene tiparvovec.
This was at a time interval when immune suppression had already
been discontinued. This phenomenon was observed across the
three studies and showed that fasting TG levels are not a sufficiently
sensitive marker to monitor the long-term therapeutic effects of
alipogene tiparvovec. Post-prandial chylomicron clearance kinet-
ics has been recognized as the most relevant biological marker for
the systemic activity of LPL during the clinical development of ali-
pogene tiparvovec (50, 51). However, post-prandial chylomicron
level measurements were included as endpoint only in the last of
the three interventional studies, CT-AMT-011-02. The results have
been reported (51) and show that the post-prandial chylomicron
plasma levels are significantly reduced in all patients included in
the study, independently of the presence of humoral (all patients)
or cellular systemic (two on five patients) or local (three on five
patients) immune responses against AAV1 (Figure 3), thus indi-
cating that these responses had no influence on the efficacy of
alipogene tiparvovec.
Furthermore, an ongoing study has shown a reduction in acute
pancreatitis events in a series of more than 25 affected subjects
(43). The analysis for a treatment-effect of Glybera taking into
account exposure time demonstrated a significant and clinically
relevant reduction in the risk of definite acute pancreatitis during
various periods ranging from 2.5 to 10 years pre-treatment to
post-treatment (median 2.9 years) (52).
EFFECT OF IMMUNOSUPPRESSANTS ON
TREATMENT-EMERGENT IMMUNE RESPONSES
Study CT-AMT-010, the first clinical study with AAV1–LPLS447X,
was performed without treating the patients with immunosup-
pressants. In this study, no antibody or T-cells responses against
LPL were found. However, antibodies against AAV1 capsid epi-
topes were observed in all patients whereas a T-cell response
against AAV1 was detected only in four of the eight subjects.
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FIGURE 5 |TG responder status in relation with humoral and
systemicT-cell response against AAV. The table below provides an
overview of the individual patient cellular and humoral immune responses
in relation with the clinical end point (fasting) total plasma TG. A T-cell
response to the antigen was reported transient positive (transient) when
at least two consecutive sampling time points were measured positive in
the ELISpot assay. The patient reported “sporadic” present recurrent
non-consecutive T-cell response over time. When none, or only one
sampling time was reported positive, the T-cell response was reported
negative (−).
As discussed, none of these immune responses raised specific
safety concerns. However, they triggered more a concern about
the efficacy of the product; especially the development of any
AAV-specific T-cells (48) that were thought at the time to pos-
sibly hamper the expression of LPL. A similar T-cell response
was observed in gene therapy trial for hemophilia B, in which
an AAV2 vector was used to deliver the human coagulation fac-
tor IX (24, 41, 42). In this trial, two patients developed a T-cell
response to AAV2 capsid proteins, which was not predicted from
pre-clinical studies. In those two patients, transgene expression
declined subsequently to pre-treatment levels. Based on these
observations, it was concluded by the investigators that a cyto-
toxic T-lymphocyte response to the capsid may have contributed
to a loss of transgene-expressing cells.
These discussions heavily influenced the decision to include an
immunosuppressant regimen in the clinical study protocols for
CT-AMT-011-01 as well as CT-AMT-011-02.
As a result of these discussions, 17 patients (12 in CT-AMT-011-
01 and 5 in CT-AMT-011-02) treated with alipogene tiparvovec
received a concomitant administration of immunosuppres-
sants. Treatment-emergent anti-AAV1 antibody responses were
observed in all the patients and were not affected by the immuno-
suppressants, neither during the time of administration nor after
cessation of the administration. The AAV1–LPLS447X vector used
cannot induce expression of viral proteins in host cells. Hence,
AAV1 capsid proteins are expected to be only transiently presented
to the immune system of the recipient after injection of AAV1–
LPLS447X (3, 19, 53). Therefore, the immune suppressants drugs
were given for a period of 12 weeks. A 12-week-period was con-
sidered to be sufficient for prevention of capsid immunogenicity,
based on observations in monkeys (19) and the investigators early
observations in humans that indicated TG levels started to rise after
an initial decrease usually at some time between 4 and 12 weeks
post-dosing. A combination of cyclosporine and MMF was cho-
sen because this combination is widely used to prevent cytotoxic
T-cell responses in transplant rejection. The doses of the immune
suppressants proposed to co-administer with alipogene tiparvovec
were according to approved doses for transplant rejection.
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FIGURE 6 | Effect of immune suppression on LPL-expression and
immune responses upon administration of alipogene tiparvovec.
In study CT-AMT-011-01, humoral and cellular immune
responses against AAV1 capsid proteins were observed. These
responses were similar to those observed in study CT-AMT-010
although in study CT-AMT-011-01, a higher dose of AAV1–
LPLS447X was used (Figure 4). Therefore, the immunosuppres-
sant regimen was further optimized in study CT-AMT-011-02 by
starting administration of cyclosporine and MMF administration
earlier before alipogene tiparvovec administration, and by adding
a bolus injection of methylprednisolone at the time of alipogene
tiparvovec administration. However, in study CT-AMT-011-02,
comparable humoral and cellular immune responses against
AAV1 capsid proteins were observed as in study CT-AMT-011-01
(Figure 4).
The effect of immunosuppressants on LPL-expression and
immune responses upon administration of alipogene tiparvovec
is summarized in Figure 6. In the clinical development of ali-
pogene tiparvovec, no untoward side effects were observed that
could be assigned to the use of prednisolone or one of the other
immunosuppressants.
CLINICAL DATA
CHEMISTRY AND HEMATOLOGICAL VALUES
Patients were monitored for up to 12 weeks post alipogene
tiparvovec administration regarding routine hematology and
biochemistry including CPK and CRP, increases of which are
expected in case of local inflammatory damage at the injection
site. In addition, other inflammatory markers such as neutrophil
counts were also determined at several pre- and post-exposure
occasions in the patients. None of the patients had neutrophil
counts outside the normal range. A per-patient summary of the
CRP and CPK data is given in Figure 7. The majority of the
patients had normal CRP and CPK levels pre- and post-exposure
to alipogene tiparvovec, suggesting that inflammatory reactions
in the injected muscle were mild, if present, and of little clinical
significance.
ADVERSE EVENTS
Alipogene tiparvovec was administered via a one-time set of intra-
muscular injections in the lower limbs. No consistent change in
any laboratory parameter, linked to the administered product, was
observed, including CPK. Injections were well tolerated with mild–
moderate local injection site reactions lasting for a few days relating
to the injection sites, and no change in muscle function. None of
the patients showed clinical signs of persistent local inflamma-
tion at injection sites such as redness, swelling, warmth, pain, or
dysfunction, upon administration of alipogene tiparvovec. There
are to date no reports of muscle dysfunction in LPLD patients
administered with alipogene tiparvovec.
The adverse reactions observed during the clinical development
of alipogene tiparvovec are summarized in Figure S1 in Supple-
mentary Material. Most of the adverse reactions were related to
the administration procedure. All were of transient nature and
resolved within days after the administration of the product. Only
one serious adverse event involving muscle was seen, that was
considered to be at least possibly related to alipogene tiparvovec
by the Investigator (#01-002 in CT-AMT-011-02). In this subject,
at 15 weeks post-administration, a transient rise in CPK, accom-
panied by a rise in CRP (Figure 7), was correlated with a low
positive AAV cellular response associated with no LPL-related cel-
lular or humoral significant response was seen in a complex of
clinical symptoms and signs indicated as “polyarthralgia of impre-
cise origin.” The subject show sporadic systemic T-cell responses
against AAV across the observation period at weeks 2, 8, 14, 39.
Despite those T-cell responses, the muscle biopsy of this subject
which was taken 30 weeks post alipogene tiparvovec showed robust
LPL-expression. In addition, the subject did not show any anti-LPL
cellular or humoral response (50). No adverse effect was observed
that could have been related to the immune responses discussed
in the previous paragraphs.
From the clinical data obtained across studies, we conclude that
there is no clinical untoward impact of the delivery of alipogene
tiparvovec.
DISCUSSION
To evaluate the immunogenicity of alipogene tiparvovec, an exten-
sive testing program was performed that included the analyses of
antibody and T-cell responses to LPL as well as to AAV1. Antibody
and cellular responses were measured pre-exposure to alipogene
tiparvovec, and at various occasions post-exposure. In addition,
biopsies were taken from the injected muscle and non-injected
muscle as control, to evaluate local immune and inflammatory
processes. Finally, CPK and CRP levels and neutrophil counts
were measured, and patients were clinically evaluated for local
and systemic symptoms indicative for inflammatory or immune
reactions. Expression of LPL in the injected muscle as well as the
improvement of post-prandial chylomicrons clearance in plasma
was used as biochemical markers for efficacy.
The success of in vivo gene therapy not only depends on the
ability to control the immune response toward the vector, but
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FIGURE 7 | A per-patient summary of CRP and CPK values pre- and
post-exposure to alipogene tiparvovec. Scheduled visits pre-treatment and
post-treatment have been included. The post-treatment visits were at day 1
and weeks 1, 2, 4, 8, and 12 for studies CT-AMT-010 and CT-AMT-011-01.
Weeks 14, 26, 39, and 52 were added for study CT-AMT-011-02. In the study
AMT-011-01, the isolated elevation of CRP for subject 014 was concomitant
with a transient medical condition. In the study AMT-011-02, the isolated
elevation of CRP for subject 01-001 was concomitant with a transient medical
condition. The isolated elevation of CRP and CPK for subject 01-002 was
related to the general clinical condition of the subject.
also to monitor any potential reaction to the therapeutic protein
expressed from the transgene. The data obtained from patients
with LPL-deficiency who received a single treatment with multiple
injections of alipogene tiparvovec, support the initial expecta-
tion that the protein product is minimally immunogenic, if at
all: neither treatment-emergent antibody responses against LPL
nor T-cells responses against LPL were found. Thus, the expressed
protein itself appears to be non-immunogenic.
Concerning anti-AAV immunity, the majority of healthy indi-
viduals are exposed to AAV during lifetime (2, 54). Hence it is
not surprising that 15 of 27 patients had pre-existing antibod-
ies against AAV1. There was no difference among patients with or
without these antibodies with regard to detectable LPL-expression
in the biopsies or improvement of post-prandial chylomicron
clearance, suggesting that pre-existing anti-AAV1 antibodies did
not appear to prevent LPL transgene expression and clinical effi-
cacy. Therefore, pre-existing anti-AAV1 antibodies likely have no
effect on the efficacy of alipogene tiparvovec following intra-
muscular administration. All patients showed treatment-emergent
antibody responses to AAV1 and there was no difference in
anti-AAV1 antibody response between the various dosing cohorts.
The markers that were used to demonstrate LPL-expression
and functionality after the delivery of alipogene tiparvovec are
complex. Therefore, the present report is focusing on LPL-
expression in muscle biopsies and post-prandial chylomicron
clearance as marker for systemic LPL activity. For the direct
measurement of LPL-expression, we made use of biopsies that
were obtained at different time points up to 12 months after
drug administration. However, and as described above, not all
patients gave their consent to this procedure which can present
some variability in the execution. Nineteen patients provided
their consent and in total 20 biopsies were obtained, which all
were examined for LPL-expression. In 12 of the 20 biopsies, LPL-
expression was found irrespective of the presence of antibodies
against AAV1. The second biochemical marker for successful gene
delivery in this review is the level of clearance of post-prandial
chylomicrons in plasma, which reflect the systemic activity of
LPL (49). This marker was however, included only in the study
CT-AMT-011-02. The post-prandial chylomicrons plasma lev-
els were shown to be significantly reduced in all five patients
included in this study, independently of the presence of anti-AAV1
antibodies.
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Altogether, these observations demonstrate that anti-AAV1
antibody responses did not exclude sustained transgene expression
nor did impair the systemic biological activity of the expressed
protein. Our results further support that treatment-emergent
anti-AAV1 antibody responses do not necessarily have any
influence on the long-term efficacy and safety of AAV-based
gene therapy.
Treatment-emergent T-cell responses against AAV1 capsids
were measured with the ELISpot assay and were observed in 18
of the 27 patients. However, it has to be noted that the patients
treated with the higher dose, 1× 1012 gc/kg, were more prompt
to develop an AAV1-specific T-cells responses. Somewhat higher
T-cell responses were noticed in some patients upon cessation
of the immunosuppressants, pointing to a suppressive effect on
the T-cell responses. It is therefore not possible to make defini-
tive conclusions regarding the effect of immunosuppressants on
T-cell responses to AAV1. The immunosuppressants did not affect
antibody levels as was expected since the regimen was mainly aim-
ing at reducing potential T-cell responses. MMF and cyclosporine
are both described to be effective in suppressing cytotoxic T-cell
responses. MMF has an effect on B-cell proliferation, because it
inhibits de novo guanosine nucleotide synthesis, a pathway com-
monly required for both T- and B-cell proliferation. Cyclosporine
specifically inhibits T-cell activation by inhibiting IL-2 production
and exerts limited, if any, effect on B-cell proliferation. Thus, the
increased anti-AAV1 titers are not surprising. Similar observations
were made in a study in monkeys (52) when administrating AAV8-
hFIX together with immunosuppressants consisting of MMF and
tacrolimus. In the third study of the three interventional studies for
alipogene tiparvovec, CT-AMT-011-02, prednisolone was admin-
istered in the form of a bolus injection to prevent the release of
substances that mediate inflammation and to enhance the potency
of the other immunosuppressants used.
Our studies should be considered in the context of the grow-
ing body of clinical and pre-clinical studies evaluating the role
of capsid-specific T-cells in AAV gene. The immunogenicity data
found in the clinical studies conducted with AAV-based vectors
in human, show that immune responses against AAV capsid pro-
teins can vary widely and amongst others are influenced by the
target organ, route of delivery, and dosing schedule. When tar-
geting the muscle in humans, T-cell responses directed to the
capsid antigen were documented in AAT-deficient subjects receiv-
ing intra-muscular injection of an AAV1–AAT vector (25, 55), in
study on AAV1-α-sarcoglycan in limb-girdle muscular dystrophy
subjects (35) and in our own LPL-deficient subjects. The contro-
versial aspect of the capsid-specific T-cell hypothesis is whether
the vector sensitizes transduced cells to become targets for CTL-
mediated clearance by virtue of MHC presentation of peptides
from the input capsid protein. Also, immune modulation was
used which could have impacted on the AAV-specific immune
responses, our study provides the most direct and extensive test
of this hypothesis because we observed transgene expression until
52 weeks (long-term follow-up) after injection of AAV1–LPLS447X
in the muscle, despite the detection of circulating T-cell specific
for AAV capsid peptides in some subjects and persistent focal infil-
trates in all subjects for whom transgene expression was detected.
These data clearly demonstrate that transgene expression can
persist, despite the presence of capsid-specific T-cells and cellu-
lar infiltrates. Sustained transgene expression in the presence of
T-lymphocyte responses have been reported in the literature in
experimental animals and in different tissues (56, 57) and humans
(25, 35, 37). However, whereas attention has been focused initially
on the AAV capsid as target of an undesirable T-cell response (24,
41, 42), observations made by the groups of Dr C. Walker (58) and
supported by observations of others (59) suggest that loss of func-
tion and programed death by most tissue-infiltrating AAV-primed
T-cells seem to argue against their direct participation in clearance
of AAV-vector-transduced target cells. It has been described that
T-cells in AAV-vectors related infiltrates present characteristics of
anergy (55). Such T-cell infiltrates are therefore generally consid-
ered as unable to initiate cellular self-destruction and therefore do
not impact on efficacy of transgene expression.
Another mechanism via which T-cells may affect LPL-
expression is stimulating the proliferation and differentiation of
B cells that subsequently form antibodies against AAV1. How-
ever, as is discussed above, anti-AAV1 antibodies seem to have
no impact on LPL-expression and there is no evidence whether
antibody-dependent cell-mediated cytotoxicity played a role. As
mentioned before, a sustained long-term transgene expression was
observed after intra-muscular injection, despite the presence of
circulating antibodies directed against the AAV1 capsid peptides.
The results obtained with alipogene tiparvovec demonstrate that
the presence of the anti-AAV1 humoral immune response had
no apparent influence on the long-term efficacy of the therapy.
The same observation has been reported in other clinical studies
(25, 35, 37, 47, 55).
Multiple intra-muscular injections of the vector and supposed
inflammatory and immune reactions ensuing at the injection sites
raise concerns about inflammatory damage in the injected muscle.
However, except for transient mild local procedural symptoms at
the injection sites, no clinical symptoms such as swelling, pain,
or dysfunction pointing at inflammatory damage were observed
in the patients. In addition, serial monitoring of CRP and CPK
revealed normal levels of these markers in most patients. Occa-
sional elevations of CRP and CPK were seen in two and in one
patient, respectively, without any clinical correlation. In addition,
though a mild mononuclear infiltrate was observed in 14 of the 19
patients of whom a biopsy was obtained, this infiltrate lacked sub-
stantial cytotoxic T-cells activity. Hence, no clinical, biochemical,
histochemical, or immunological evidence for inflammatory mus-
cle damage at the injections sites was found.
All together, the data collected on systemic and local immune
responses induced by intra-muscular injection of alipogene tipar-
vovec demonstrate the absence of impact on safety and did not
compromise LPL transgene expression. These findings indicate
that muscle-directed AAV-based gene therapy through the intra-
vascular route remains a promising approach for the treatment of
human diseases.
REGULATORY PERSPECTIVE
During the assessment of the Glybera marketing authorization
dossier, the fact that no responses had been seen against the
expressed LPL protein was considered as a positive safety asset
and no material concerns were expressed.
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The necessity of using immunosuppressants was not proven
during the clinical development of Glybera since the regimen
seemed not to improve efficacy whilst having a major negative
impact on the safety aspects. It remains questionable whether it
makes clinical sense to co-administer immunosuppressants with
any AAV-based vector. However, in the case of Glybera, since LPLD
is such a rare disease, it will not be possible to further assess
long-term clinical efficacy in absence of any immunosuppressants
within the present indication.
During the regulatory review by the European Medicines
Agency, multiple questions arose on whether the cellular responses
to the viral capsid proteins could have any meaningful negative
effect on the long-term safety or efficacy of alipogene tiparvovec.
Our data clearly demonstrate that transgene expression can persist,
despite the presence of capsid-specific T-cells and cellular infil-
trates and without apparent toxicity or attenuation of transgene
expression. Furthermore, the purity of the vector preparations (in
terms of total amount of viral proteins injected versus dose in
genome copies) and impurities profile of the vectors used in the
various clinical trials described in the literature may be very diver-
gent and therefore may lead to very different immune responses.
Nonetheless, the scientific debate has been powerfully influenced
by previous findings with other vectors and by the hypothesis that
the vector sensitizes transduced cells to become targets for CTL-
mediated clearance. Therefore, since the safety data on alipogene
tiparvovec have been collected in a small number of patients, their
clinical relevance and possible interpretations were considered not
fully unequivocal and further data collection has been requested by
the European Medicine Agency post-approval of Glybera®. Such
data will be collected from all treated patients in future in a LPLD
registry, thus allowing for long-term data analysis.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00082/
abstract
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